In MS, CSF T cells are enriched for those expressing CD20+, but are still <50% of CSF T cells (45) suggesting that the CSF T cell reduction observed after RTX treatment cannot be fully explained by their lysis by anti-CD20 mAb. Here, CSF2 is linked to myeloid sarcoma.